New Delhi, March 2: Indian COVID-19 vaccine maker Bharat Biotech on Wednesday released results of the Phase 3 clinical trial of Covaxin. The efficacy of Covaxin has been confirmed to be 81 percent in the Phase 3 trials. According to Bharat Biotech, the trials involved 25,800 subjects. The demonstrates 81 percent interim efficacy in preventing COVID-19 in those after the second dose. Notably, Covaxin is India's first indigenous vaccine for COVID-19. Bharat Biotech Confirms Deal with Brazil to Supply 20 Million Doses of COVID-19 Vaccine Covaxin.
The Indian COVID-19 vaccine maker said, "COVAXIN has demonstrated an interim vaccine efficacy of 81% in its Phase 3 clinical trial. The trials involved 25,800 subjects, the largest ever conducted in India, in partnership with ICMR." The company also claimed that the vaccine is effective against the UK variant of COVID-19.
Tweet by ANI:
COVAXIN has demonstrated an interim vaccine efficacy of 81% in its Phase 3 clinical trial. The trials involved 25,800 subjects, the largest ever conducted in India, in partnership with ICMR: Bharat Biotech pic.twitter.com/jDIka9LIEE
— ANI (@ANI) March 3, 2021
Clinical trials will continue through to final analysis These analysis will be conducted at 130 confirmed cases to collect data for evaluating the efficacy of the vaccine candidate. In Phase 1 and Phase 2 clinical trials, Covaxin demonstrated the ability to produce antibodies against COVID-19. COVID-19 Vaccine Latest Update: Covishield and Covaxin Get Approval by DCGI for Emergency Use in India.
On Monday, PM Narendra Modi also received the first shot of Covaxin. The Indian government has so far procured 5.5 million doses of Covaxin and issued a letter of comfort to company for another 4.5 million doses. Serum Institute of India's Covishield and Covaxin received approval from the Indian government for usage against COVID-19 in January this year.
(The above story first appeared on LatestLY on Mar 03, 2021 05:53 PM IST. For more news and updates on politics, world, sports, entertainment and lifestyle, log on to our website latestly.com).